Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealth Alliance Plan Medicare Part B Prior Auth Up…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedHealth Alliance Plan (HAP)Policy N/A

    Medicare Part B Prior Authorization and Step Therapy Criteria

    Customize your policy alerts

    Sign up for all Health Alliance Plan (HAP) policy alerts

    Know when Health Alliance Plan (HAP) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines HAP Medicare Part B prior authorization and step therapy requirements, clinical review approach, and documentation expectations for outpatient drugs/biologics administered under Medicare Part B. Affects providers requesting coverage for Part B drugs for HAP Medicare members.

    Policy Summary
    PayerHealth Alliance Plan (HAP)
    PolicyMedicare Part B Prior Authorization and Step Therapy Criteria
    Policy CodePolicy N/A
    Change TypeMaterial updates to PA/step requirements and documentation
    Effective DateJan 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with required medical records (including genetic, staging, and prior-therapy documentation where indicated) via the HAP Provider Portal.
    SourceLink
    POLICY UPDATE CHANGES

    Effective 1/1/2026 Amvuttra (vutrisiran) injection has required medical information fields and age restriction specified.

    For ATTR-related familial amyloid polyneuropathy, documentation must include a transthyretin (TTR) mutation, baseline PND score <= IIIb and/or FAP Stage 1 or 2, and clinical signs/symptoms.

    Age restriction: patient must be at least 18 years of age for transthyretin amyloid cardiomyopathy and ATTR indications.

    Docetaxel (J9171) coverage effective 4/1/2026 includes requirement to first try the covered docetaxel drug identified by J9171 and coverage duration up to 1 year.

    Evkeeza (evinacumab-dgnb) coverage effective 1/1/2026: 1-year duration; prescriber must be or consult cardiologist, endocrinologist, or lipidologist; submit most recent LDL-C.

    Epysqli (eculizumab-aagh) detailed indication-specific criteria included (NMOSD, myasthenia gravis, aHUS, PNH) with prior trials and reauthorization requirements.

    Evenity (J3111 romosozumab-aqqg) limited to 12 months per lifetime and requires prior failure of Prolia.

    Exdensur (depemokimab-ulaa J2361) effective 7/1/2026: requires elevated eosinophils ≥150 and prior controller therapies; prescriber must be allergy/immunology/pulmonology; up to 1 year.

    Medicare Part BBenefit governed
    >=18Minimum age
    4Required documentation items
    1 yearTypical coverage duration
    1/1/2026Amvuttra effective
    90-dayTransition period

    Coverage Criteria and Drug-Specific Rules

    General medical necessity

    Covered when drug is used for a medically accepted indication and documentation supports medical necessity per Medicare guidance or HAP criteria.

    General coverage requirements: Use of the drug for a Medically Accepted Indication as defined by CMS (NCD/LCD/LCA) or, when absent, by CMS‑approved compendia and current evidence; supporting medical records must be provided to demonstrate medical necessity.

    Providers are responsible for checking applicable Medicare coverage guidance; Medicare guidance supersedes HAP where conflict exists.

    Selected drug-specific coverage criteria (examples)

    Drug-specific examples with mandatory pre-requisites and exclusions (partial extracts from the document):

    Hemophilia prophylaxis drugs: Must not be used in combination with other drugs indicated for prophylaxis for hemophilia A or B; member must have documentation of hemophilia A or B without inhibitors; prior trials of specified prophylaxis agents required (for hemophilia A: trial of two prophylaxis drugs with one being Hemlibra; for hemophilia B: trial of two prophylaxis drugs such as Alprolix, BeneFIX or Idelvion).
    Policy Summary
    PayerHealth Alliance Plan (HAP)
    PolicyMedicare Part B Prior Authorization and Step Therapy Criteria
    Policy CodePolicy N/A
    Change TypeMaterial updates to PA/step requirements and documentation
    Effective DateJan 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with required medical records (including genetic, staging, and prior-therapy documentation where indicated) via the HAP Provider Portal.
    SourceLink
    On This Page
    Coverage Criteria and Drug-Specific RulesBilling Codes and Clinical Key ValuesPrior Authorization, Documentation, and Step Therapy — Provider ActionsInitial Authorization / Step Therapy — CriteriaReauthorization and Continuation RequirementsStep Therapy Pathways and Required TrialsQuantity, Duration and Administration LimitsSite of Care and Administration NotesBiosimilar Preference and Required TrialsBackground and ScopeDefinitions and Clinical Thresholds

    Prescription for concizumab/marstacimab must be written by a hematologist per prescriber restriction.

    Transthyretin‑targeted therapies (example Amvuttra/vutrisiran): Must not be used in combination with TTR stabilizers (e.g., tafamidis) or TTR‑lowering agents (e.g., Onpattro) and patient must not have had a liver transplant; required documentation includes a pathogenic transthyretin (TTR) mutation (e.g., V30M), baseline PND score ≤ IIIb and/or FAP Stage 1 or 2, and clinical signs/symptoms of disease.PND <= IIIb or FAP Stage 1-2

    Dose and duration approved per FDA labeling or accepted standards (examples: up to 1 year).

    Initial coverage criteria — ATTR‑FAP

    Covered when ALL of the following are met for Transthyretin‑related familial amyloid polyneuropathy (ATTR‑FAP):

    ATTR-FAP initial criteria: 1) Medical records supporting the request are provided; AND 2) Documentation of a transthyretin (TTR) mutation (e.g., V30M); AND 3) Documentation of a baseline polyneuropathy disability (PND) score less than or equal to IIIb and/or baseline FAP Stage 1 or 2; AND 4) Documentation of clinical signs and symptoms of the condition (e.g., motor disability, peripheral or autonomic neuropathy).PND <= IIIb or FAP Stage 1-2

    Initial coverage criteria — Transthyretin amyloid cardiomyopathy

    Covered when ALL of the following are met for Transthyretin amyloid cardiomyopathy (wild-type or hereditary):

    Cardiomyopathy criteria: 1) Confirmation of diagnosis with appropriate testing; AND 2) Medical records supporting the request are provided; AND 3) Patient is at least 18 years of age; AND 4) Documentation of clinical signs/symptoms as applicable.Age >= 18 years

    May require documentation of TTR mutation where applicable (e.g., V30M).

    Initial coverage criteria — familial amyloid polyneuropathy

    Covered when ALL of the following are met for transthyretin-related familial amyloid polyneuropathy (hATTR):

    hATTR coverage criteria: 1) Medical records supporting the request are provided; AND 2) Documentation of a transthyretin (TTR) mutation (e.g., V30M); AND 3) Documentation of a baseline polyneuropathy disability (PND) score <= IIIb and/or baseline FAP Stage 1 or 2; AND 4) Documentation of clinical signs and symptoms of the condition (e.g., motor disability, peripheral/autonomic neuropathy).PND <= IIIb or FAP Stage 1-2

    Initial coverage criteria — cardiac amyloidosis

    Covered when ALL of the following are met for transthyretin amyloid cardiomyopathy (wild-type or hereditary):

    cardiomyopathy coverage criteria: 1) Confirmation of diagnosis with appropriate testing; AND 2) Patient is at least 18 years of age; AND 3) Medical records supporting the request are provided; AND 4) Documentation of relevant baseline polyneuropathy disability and clinical signs/symptoms where applicable.Age >= 18 years

    Coverage duration and dosing per FDA labeling or accepted standards (examples: up to 1 year).

    Initial coverage criteria

    Covered when ALL of the following are met (documented across the policy text):

    Age: Patient is at least 18 years of age.>= 18 years
    Diagnosis confirmation: Confirmation of transthyretin amyloid cardiomyopathy diagnosis with appropriate testing; include TTR mutation documentation where applicable.
    Clinical baseline: Documentation of baseline polyneuropathy disability and clinical signs and symptoms where applicable.PND <= IIIb or FAP Stage 1-2

    Referenced as part of required numbered criteria.

    Transthyretin amyloid cardiomyopathy (wild-type or hereditary) — initial coverage criteria

    Covered when ALL of the following are met:

    Initial coverage requirements: 1) Confirmed diagnosis of transthyretin amyloid cardiomyopathy (wild-type or hereditary) with appropriate testing; AND 2) Patient is at least 18 years of age; AND 3) Patient has tried and failed Attruby; AND 4) Medical records supporting prior therapies and responses are provided.

    Dose and duration approved according to FDA labeling or accepted standards; coverage duration examples up to 1 year.

    Epigslist / Epysqli Indication-specific Coverage

    Epigslist (eculizumab-aagh) covered when ALL of the following are met (by indication):

    NMOSD criteria: 1) Anti‑AQP4 antibody positive disease; AND 2) Presence of qualifying core clinical characteristics (e.g., optic neuritis, acute myelitis, area postrema syndrome, etc.); AND 3) Trial and failure of Uplizna; AND 4) Trial and failure of Enspryng; AND 5) EDSS score ≤ 7; AND 6) Not used in combination with Ultomiris, Uplizna, Enspryng or other NMOSD medications; AND 7) For reauthorization: documentation of decreased relapse rate.EDSS <= 7

    Prescribed by or in consultation with a neurologist; coverage up to 1 year.

    Myasthenia gravis criteria: 1) Baseline MG‑ADL score ≥ 6; AND 2) Confirmed generalized MG that is anti‑AChR antibody positive; AND 3) Trial of one non‑steroidal generic immunosuppressant for ≥ 6 months with inadequate response or intolerance; AND 4) For reauthorization: not used in combination with similar MG therapies and documentation of improvement in MG‑ADL from baseline.MG‑ADL >= 6

    Prescribed by or in consultation with a neurologist; coverage up to 1 year.

    aHUS criteria: 1) Shiga‑toxin related HUS and TTP ruled out; AND 2) For reauthorization: documentation of decreased thrombotic microangiopathy (e.g., normalization of platelets and LDH; reduction in serum creatinine).
    PNH criteria: 1) Diagnosis confirmed by flow cytometry; AND 2) Hemolysis‑associated symptoms present; AND 3) Not used in combination with other complement drug therapy (e.g., Fabhalta, Ultomiris, Empaveli); AND 4) For reauthorization: documentation of clinical and hematologic improvement (e.g., reduced transfusions, improved hemoglobin).

    Evenity Initial Therapy

    Evenity (romosozumab‑aqqg J3111) covered when ALL of the following are met:

    Prior therapy: Must try and fail Prolia (failure defined as intolerance, decrease in BMD vs prior DEXA, new fracture while on therapy, or contraindication).
    Prescriber: Prescribed by an endocrinologist.
    Duration: Coverage limited to 12 months per lifetime.12 months per lifetime

    Cumulative use beyond 12 months is not covered.

    Exdensur Initial Therapy

    Exdensur (depemokimab-ulaa J2361) covered when ALL of the following are met:

    Eosinophil threshold: Elevated eosinophil level ≥ 150 cells/µL.>= 150
    Prior therapy: Trial of controller therapies (e.g., LABA, LAMA, leukotriene receptor antagonist or interleukin drug) or one asthma exacerbation requiring hospitalization in past 12 months, as applicable.
    Prescriber: Prescribed by or in consultation with an allergist, immunologist, or pulmonologist.
    Duration: Coverage up to 1 year; dosing per FDA labeling or accepted practice.1 year

    Biosimilar and product-specific step therapy

    Biosimilars and alternative-preference rules (examples):

    Fulphila: Must first try Neulasta, Udenyca, AND Nyvepria before Fulphila coverage; coverage duration up to 1 year.
    Herceptin products and trastuzumab biosimilars: Must first try Trazimera AND Kanjinti prior to coverage of Herceptin, Herceptin Hylecta, Hercessi, or Herzuma; coverage duration typically 1 year and dosing per FDA labeling.

    Ophthalmic agent coverage criteria

    Intravitreal anti‑VEGF and aflibercept family coverage notes:

    Avastin trial: Must try Avastin (bevacizumab) prior to coverage of aflibercept/Eylea family products.
    Eylea HD specific: Protocolized dosing/failure definitions apply (bolus every 4 weeks for required initial doses and maintenance trials per criteria); failure defined as no improvement, worsening, or intolerance after required dosing for at least 12 weeks.

    Hympavzi Initial Therapy

    Hympavzi (marstacimab J7172) coverage when ALL met:

    Diagnosis: Member must have documented hemophilia A without inhibitors or hemophilia B; must not be receiving other prophylaxis drugs in combination.
    Prescriber: Prescription must be written by a hematologist.
    Dosing: Initial loading dose 300 mg (two 150 mg injections) by subcutaneous injection followed by maintenance 150 mg weekly starting one week after loading; dose escalation to 300 mg weekly requires documentation of medical necessity (e.g., increased spontaneous bleeding).
    Prior prophylaxis trials: For hemophilia A: trial of two prophylaxis drugs including Hemlibra; for hemophilia B: trial of two prophylaxis drugs such as Alprolix, BeneFIX or Idelvion.

    Trastuzumab biosimilars (Hercessi, Herzuma)

    Covered when ALL of the following are met:

    Trastuzumab biosimilar coverage: 1) Use is for a medically accepted indication; AND 2) Medical records provided documenting prior therapies and responses; AND 3) Must first try Trazimera AND Kanjinti; AND 4) Dose approved per FDA labeling or accepted standards; AND 5) Coverage duration: 1 year.

    Marstacimab (Hympavzi / J7172) coverage

    Covered when ALL of the following are met:

    Marstacimab criteria: 1) Use for a medically accepted indication (hemophilia A without inhibitors or hemophilia B) with medical records provided; AND 2) Not used in combination with other prophylaxis drugs for hemophilia; AND 3) Prescription written by a hematologist; AND 4) Prior prophylaxis trials as described; AND 5) Dosing per initial loading and maintenance schedule; AND 6) Coverage duration up to 1 year.

    Dose escalation requires documented medical necessity.

    iDose TR / J7355 (travoprost intracameral implant) coverage

    Covered when ALL of the following are met:

    iDose TR coverage: 1) Medical records supporting the request are provided; AND 2) Patient has open‑angle glaucoma or ocular hypertension; AND 3) One of: (a) patient has tried and failed one generic prostaglandin eye drop (e.g., latanoprost, bimatoprost, travoprost) AND Durysta; OR (b) patient cannot use Durysta and has tried and failed two generic topical prostaglandin eye drops; AND 4) 'Failed' defined as inadequate response, intolerance, or documented compliance issues; AND 5) The requested eye must not have received prior treatment with IDOSE TR.

    One‑time administration per FDA labeling; prescriber/age restrictions listed as N/A in policy.

    Initial therapy / authorization criteria

    Covered when ALL of the following are met

    Main criteria: 1) Medical records supporting the request are provided; AND 2) Patient has open‑angle glaucoma or ocular hypertension; AND 3) One of the following: (a) patient has tried and failed one generic prostaglandin eye drop (e.g., latanoprost, bimatoprost, travoprost) AND Durysta; OR (b) patient is not able to use Durysta and has tried and failed two generic topical prostaglandin eye drops.

    'Failed' defined as inadequate response, intolerance, or demonstrated compliance issues.

    Initial therapy/authorization criteria

    Covered when ALL of the following are met

    Main criteria: 1) Medical records supporting the request are provided; AND 2) Patient has open‑angle glaucoma or ocular hypertension; AND 3) Either: (a) trial and failure of one generic prostaglandin topical agent plus Durysta; OR (b) inability to use Durysta and trial/failure of two generic topical prostaglandin agents.

    Failure = inadequate response, intolerance, or demonstrated compliance issues.

    Initial therapy

    Covered when ALL of the following are met

    Overall requirements: 1) Medical records supporting the request are provided; AND 2) Patient has open‑angle glaucoma or ocular hypertension; AND 3) Patient meets one of the prior‑therapy pathways (see any node).
    Prior therapy options: a) Patient has tried and failed one generic prostaglandin eye drop (latanoprost, bimatoprost, or travoprost) AND Durysta; OR b) Patient cannot use Durysta and has tried and failed two generic topical prostaglandin eye drops.

    'Failed' = inadequate response, intolerance, or compliance issues.

    Initial therapy criteria

    Covered when ALL of the following are met

    Main coverage criteria: 1) Patient has open‑angle glaucoma or ocular hypertension; AND 2) Patient meets one of: (a) tried and failed one generic prostaglandin eye drop (latanoprost, bimatoprost, travoprost) AND Durysta; OR (b) unable to use Durysta and tried and failed two generic topical prostaglandin eye drops.

    Failure defined as inadequate response, intolerance, or demonstrated compliance issues.

    Initial therapy / Approval criteria

    Covered when ALL of the following are met

    Main coverage criteria: 1) Patient has open‑angle glaucoma or ocular hypertension; AND 2) Patient meets one of the prior therapy pathways (a OR b).
    Prior therapy pathways: a) Trial and failure of one generic prostaglandin eye drop (latanoprost, bimatoprost, or travoprost) AND Durysta; OR b) Patient unable to use Durysta and trial/failure of two generic topical prostaglandin eye drops.

    'Failed' defined as inadequate response, intolerance, or compliance issues.

    Initial authorization criteria

    Covered when ALL of the following are met:

    Indication: Patient has open‑angle glaucoma or ocular hypertension.
    Prior therapy options: One of: (a) trial and failure of one generic prostaglandin eye drop (e.g., latanoprost, bimatoprost, travoprost) AND Durysta; OR (b) patient cannot use Durysta and has tried and failed two generic topical prostaglandin eye drops.

    Failed defined as inadequate response, intolerance, or documented compliance issues.

    Initial therapy / coverage criteria

    Covered when ALL of the following are met:

    Main coverage criteria: 1) Medication use is for a medically accepted indication; AND 2) Patient has open‑angle glaucoma or ocular hypertension; AND 3) One of: (a) trial and failure of one generic prostaglandin eye drop AND Durysta; OR (b) unable to use Durysta and trial/failure of two generic topical prostaglandin eye drops.

    Failure = inadequate response, intolerance, or demonstrated compliance issues.

    Administration frequency

    Administration constraint:

    Administration: One‑time administration as indicated per FDA‑approved labeling or within the labeling timeframe.one-time administration

    Applicable to iDose TR (J7355).

    Initial Coverage Criteria

    Covered when ALL of the following are met:

    Primary criteria: 1) Use is for a medically accepted indication; AND 2) Patient has open‑angle glaucoma or ocular hypertension; AND 3) Patient meets one of: (a) tried and failed one generic topical prostaglandin eye drop (e.g., latanoprost, bimatoprost, travoprost) plus Durysta; OR (b) patient is not able to use Durysta and has tried and failed two generic topical prostaglandin eye drops.

    'Failed' = inadequate response, intolerance, or demonstrated compliance issues.

    For transthyretin-related therapies, coverage is denied when used in combination with transthyretin (TTR) stabilizers (for example, tafamidis) or TTR-lowering agents (for example, Onpattro), or when the member has had a prior liver transplant. Medical records supporting the request must be provided, including documentation of the required diagnostic and staging information (see specific criteria).

    For hemophilia prophylaxis agents, requests must include documentation of the hemophilia diagnosis (hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors) and prior prophylaxis trials; combination use with other prophylactic agents is an exclusion and will trigger denial when present.

    Age restrictions are applied for certain indications. Specifically, for transthyretin amyloid cardiomyopathy and related transthyretin indications the patient must be at least 18 years of age; age must be documented in the submitted medical records.

    Some products require specialist prescribing or consultation. For example, marstacimab (Hympavzi) prescriptions must be written by a hematologist and Evkeeza requires prescription by or consultation with a cardiologist, endocrinologist, or board-certified lipidologist. When a prescriber restriction applies it is stated in the drug-specific entry and must be met for approval.

    Several entries in the policy explicitly state there are no additional exclusions in the excerpted sections (noted as N/A for exclusions). Where exclusions are not listed, coverage decisions rely on meeting the documented criteria and required medical information.

    For Amvuttra (vutrisiran) the provided text does not list additional indication-specific exclusions in these chunks; coverage depends on meeting the required diagnostic and staging documentation described elsewhere in the policy.

    Entyvio and complement/neurologic biologics have combination-use exclusions. Entyvio must not be used in combination with other biological drugs or Otezla, and Epysqli (eculizumab-aagh) must not be used in combination with Ultomiris, Uplizna, Enspryng or other specified therapies for the relevant indications; such combination use will trigger denial.

    Hympavzi (marstacimab) must not be used in combination with other prophylaxis drugs for hemophilia A or B; combination use is an exclusion and will result in denial. The policy also requires prior prophylaxis trials and hematology prescriber documentation for approval.

    Epijnlijk/Epmysqli (eculizumab-aagh) entries explicitly prohibit combination therapy with other complement or disease-specific agents (for NMOSD, PNH, MG and aHUS) as listed per indication. Combination use with the named agents will trigger denial.

    Evkeeza (evinacumab-dgnb) must not be used in combination with PCSK9 inhibitors or with Nexletol or Nexlizet; requests must include the most recent LDL-C and meet prescriber requirements.

    Marstacimab (Hympavzi) initial dosing and combination exclusions are specified: loading and maintenance dosing requirements are set and the drug must not be used in combination with other hemophilia prophylaxis agents. Documentation of prior prophylaxis trials is required before approval.

    Where the policy lists Age N/A (for example in the iDose TR sections), no age-based restriction applies to that product in the excerpted text; approval depends on meeting the clinical and prior-therapy criteria rather than an age threshold.

    Several sections indicate both age and exclusion status are not applicable (e.g., iDose TR entries state Age Restrictions: N/A and list the exclusion that the requested eye must not have previously received IDOSE TR). Where neither age nor prescriber restrictions are present, coverage focuses on meeting prior-therapy and documentation requirements.

    When the policy states Age Restrictions: N/A it indicates no age-based exclusion is specified in that product entry; medical records and prior-therapy trials remain required per the criteria.

    In multiple iDose TR/J7355 entries the policy denotes no explicit exclusions beyond the prior-treatment exclusion (the requested eye must not have received prior IDOSE TR). Other product entries similarly show no explicit exclusions in the cited chunks.

    Several entries within the iDose TR coverage criteria show both Age Restrictions: N/A and Prescriber Restrictions: N/A, indicating that neither an age minimum nor a prescriber limitation is required for those specific criteria; approval hinges on documented diagnosis and prior topical therapy trials.

    Across the cited sections there are entries with no explicit exclusions listed. In these cases coverage determination depends on meeting the stated medical information, prior-therapy, and documentation requirements.

    Where prescriber or age restrictions are not specified (noted as N/A), the policy expects required documentation (diagnosis and prior trials) but does not mandate a specialist prescriber or an age limit for approval in the cited product entries.

    In several product entries the policy explicitly records that none of the listed age or prescriber restrictions apply (Age Restrictions: N/A; Prescriber Restrictions: N/A). Where 'none explicitly stated' is recorded, reviewers should follow the clinical criteria and documentation requirements for adjudication.

    Billing Codes and Clinical Key Values

    Example HCPCS/J-codes referencedHCPCS
    J7173Concizumab
    J0225Amvuttra (vutrisiran) injection
    Covered HCPCS CodesHCPCSCovered
    J0225Amvuttra (vutrisiran) injection
    Covered HCPCS CodesHCPCSCovered
    J0225vutrisiran injection
    Covered HCPCS CodesHCPCSCovered
    J0225Amvuttra (vutrisiran) injection (as listed)
    Covered J-CodeHCPCSCovered
    J0225Amvuttra (vutrisiran) injection
    Docetaxel and related J-codesHCPCSCovered
    J9171Docetaxel injection (preferred docetaxel J-code referenced)
    J9174Docivyx / docetaxel? (J9174 referenced in document)
    Ophthalmic/infusion J-codesHCPCSCovered
    J3590Entyvio / aflibercept J-code family referenced (generic placeholder J3590 used in doc)
    J0178Aflibercept
    J0177Aflibercept HD
    Colony stimulating factorsmixedCovered
    Pegfilgrastim (various J-codes)Fulphila / Fylnetra / Neulasta class referenced
    Fulphila (example)HCPCSCovered
    J3490Fulphila (pegfilgrastim-jmdb) referenced in step therapy notes (placeholder J3490)
    Trastuzumab productsHCPCSCovered
    J9355Herceptin
    J9356Herceptin Hylecta (trastuzumab/hyaluronidase)
    Osteoporosis biologicHCPCSCovered
    J3111Romosozumab-aqqg (Evenity)
    Lipid-lowering monoclonal antibodyHCPCSCovered
    J1305Evkeeza (evinacumab-dgnb)
    Hemophilia prophylaxisHCPCSCovered
    J7172Hympavzi (marstacimab hncq) injection
    Hemophilia prophylaxis agentHCPCSCovered
    J7172marstacimab hncq inj
    iDose TR (travoprost) intracameral implantHCPCSCovered
    J7355travoprost intracameral implant (iDose TR)
    Covered HCPCS CodesHCPCSCovered
    J7355travoprost intracameral implant
    Covered HCPCS CodesHCPCSCovered
    J7355iDose TR (travoprost) intracameral implant
    Covered HCPCSHCPCSCovered
    J7355iDose TR (travoprost) intracameral implant
    Covered HCPCS/CPT CodesHCPCSCovered
    J7355travoprost intracameral implant (iDose TR)
    Covered HCPCS CodesHCPCSCovered
    J7355iDose TR (travoprost) intracameral implant
    Covered HCPCS CodeHCPCSCovered
    J7355iDose TR (travoprost) intracameral implant
    Covered HCPCS CodesHCPCSCovered
    J7355travoprost intracameral implant (iDose TR)
    Covered HCPCS CodesHCPCSCovered
    J7355iDose TR (travoprost) intracameral implant
    Baseline PND score
    Baseline PND scoreLess than or equal to IIIb
    ContextRequired for ATTR‑FAP authorization; must be documented in medical records
    Supporting evidenceReferenced alongside requirement for documented TTR mutation and clinical signs/symptoms
    Age
    Minimum age>= 18 years
    Applies toTransthyretin amyloid cardiomyopathy and related ATTR indications
    DocumentationAge must be documented in prior authorization request
    Baseline neuropathy severity
    Baseline neuropathy severityPND score <= IIIb and/or FAP Stage 1 or 2
    UseRequired for ATTR‑FAP and hATTR coverage determinations
    DocumentationMust be shown in medical records submitted with PA request
    Coverage duration
    Typical coverage durationUp to 1 year
    NotesDose and duration approved per FDA labeling or accepted standards of medical practice
    ExceptionsEvenity cumulative use limited to 12 months per lifetime (see Evenity quantity limit)
    Eosinophil level
    Eosinophil threshold>= 150 cells/µL
    IndicationRequired for Exdensur (depemokimab) eligibility
    DocumentationMust be included in medical records submitted with PA
    MG-ADL baseline
    MG-ADL baseline>= 6
    IndicationRequired baseline for Epysqli coverage in myasthenia gravis
    Reauthorization metricImprovement in MG-ADL from baseline required for reauthorization
    EDSS score
    EDSS score threshold<= 7
    IndicationRequired for Epijkstra/Epigslist (eculizumab) NMOSD coverage
    DocumentationEDSS must be documented in medical records for PA
    Marstacimab dosing
    Loading dose300 mg (two 150 mg injections) subcutaneous
    Maintenance dose150 mg weekly starting one week after loading dose
    Dose escalationAdjustments to 300 mg weekly require medical records documenting medical necessity (e.g., increased spontaneous bleeding)

    Prior Authorization, Documentation, and Step Therapy — Provider Actions

    Prior Authorization

    Prior authorization required for select Part B drugs

    Submit a prior authorization (PA) request via the HAP Provider Portal for select Medicare Part B drugs and include supporting medical records to determine coverage under the medical benefit.

    • PA may be required to determine whether the drug is covered under Medicare Part B or Part D.
    • Include supporting medical records documenting diagnosis, prior therapies, and responses as specified by the drug-specific criteria.
    Prior Authorization

    Prior authorization required for J0225

    Prior authorization is required for Amvuttra (vutrisiran) billed with J0225; requests must include the listed required medical information for the indication.

    • J0225 (Amvuttra) is effective 1/1/2026 for PA requirements.
    • Provide the specific required medical information enumerated in the Amvuttra criteria.
    Prior Authorization

    Prior authorization required

    Prior authorization is required for Amvuttra (vutrisiran J0225) and must meet the medical information criteria for the indicated transthyretin amyloidosis conditions.

    • PA applies to J0225 for transthyretin-related indications.
    • Coverage requires submission of required documentation as specified in the policy.
    Prior Authorization

    Prior authorization for Amvuttra (J0225)

    Prior authorization applies for Amvuttra (vutrisiran J0225) injection; include documentation supporting diagnosis and eligibility as specified (effective 1/1/2026).

    • Provide medical records and required diagnostic documentation per the Amvuttra criteria.
    • Policy effective date for these requirements is 1/1/2026.
    Prior Authorization

    Prior authorization required

    Prior authorization is required for Amvuttra (J0225); coverage requires confirmation of diagnosis, and for cardiomyopathy the patient must have tried and failed Attruby per the criteria.

    • Coverage duration and dosing are approved per FDA labeling or accepted standards.
    • Patient must have documentation of prior trial and failure of Attruby for cardiomyopathy indication.
    Step Therapy

    Docetaxel (J9171) prior authorization and step

    Docetaxel requires prior authorization and a step: providers must first try the covered docetaxel drug identified by J9171 before coverage of alternative docetaxel products; coverage duration is up to 1 year.

    • Must first try the covered docetaxel drug identified by J9171.
    • Dose and duration approved per FDA labeling; typical coverage duration up to 1 year.
    Prior Authorization

    Epysqli (eculizumab-aagh) PA criteria

    Epysqli (eculizumab-aagh) prior authorization must meet indication‑specific criteria (NMOSD, MG, aHUS, PNH) including required diagnostic tests, prior therapy trials, and reauthorization documentation of response.

    • NMOSD: AQP4-antibody positive, failure of Uplizna and Enspryng, EDSS ≤7, and prohibition on combination with other NMOSD agents.
    • MG: baseline MG-ADL ≥6, AChR-Ab positive, trial of a non-steroid immunosuppressant ≥6 months; reauthorization requires documented improvement.
    • aHUS and PNH: diagnostic confirmations and reauthorization evidence as specified; avoid combination with other complement therapies.
    Step Therapy

    Fulphila step therapy

    Fulphila requires step therapy: prior trials of Neulasta, Udenyca, AND Nyvepria must be documented before approval; coverage duration up to 1 year.

    • Provide medical records documenting trials and responses to preferred pegfilgrastim products.
    • Duration and dosing will follow FDA labeling or accepted standards.
    Step Therapy

    Herceptin biosimilar step requirements

    Herceptin and related trastuzumab products require prior trials of the listed biosimilars (Trazimera AND Kanjinti) before coverage; include medical records documenting prior therapies and responses.

    • Provide documentation that trials of Trazimera and Kanjinti were attempted and failed.
    • Coverage duration typically up to 1 year; dosing per FDA labeling.
    Step Therapy

    Trastuzumab biosimilars PA/ST

    Prior authorization and step therapy apply to listed trastuzumab biosimilars and reference products; must try specified biosimilars (Trazimera AND Kanjinti) before coverage of Hercessi or Herzuma.

    • Document trials and failures of the specified biosimilars in the medical records.
    • Dosing and duration follow FDA labeling or accepted standards (typically 1 year).
    Prior Authorization

    Marstacimab (Hympavzi) PA/ST

    Marstacimab (Hympavzi J7172) requires prior authorization; submit medical records documenting diagnosis, prior prophylaxis trials, and prescriber must be a hematologist; initial loading and maintenance dosing must be documented.

    • Member must have documented hemophilia A without inhibitors or hemophilia B as applicable.
    • For hemophilia A: trial of two prophylaxis drugs including Hemlibra; for hemophilia B: trial of two prophylaxis drugs such as Alprolix, BeneFIX, or Idelvion.
    • Initial loading dose 300 mg (two 150 mg injections) and maintenance 150 mg weekly; dose escalation to 300 mg weekly requires documentation of medical necessity.
    Prior Authorization

    iDose TR (J7355) PA/ST

    iDose TR (travoprost intracameral implant J7355) requires prior authorization and step therapy; requests must document diagnosis of open‑angle glaucoma or ocular hypertension and appropriate prior topical/Durysta trials per criteria.

    • Provide medical records showing diagnosis and details of prior topical prostaglandin trials and Durysta use or contraindication.
    • The requested eye must not have previously received IDOSE TR (prior same-device treatment is an exclusion).
    • Approval is for one-time administration per FDA labeling when criteria are met.
    Documentation Required

    PA/ST = Required Medical Information

    PA/step therapy requests for iDose TR must include the required medical information: medical records supporting the request, diagnosis of open‑angle glaucoma or ocular hypertension, and documentation of required prior trials.

    • Medical records must document prior use and failure (inadequate response, intolerance, or compliance issues) of specified topical prostaglandin drops and Durysta as applicable.
    • If Durysta cannot be used, document trials and failures of two generic topical prostaglandin eye drops.
    Prior Authorization

    PA required for iDose TR (J7355)

    Prior authorization is required for iDose TR (J7355); medical records must document open‑angle glaucoma or ocular hypertension and prior topical prostaglandin therapy trials per the policy criteria.

    • Include documentation of the specific topical PGA trials and Durysta use or inability to use Durysta.
    • Define and document reasons for 'failed' trials (inadequate response, intolerance, or compliance issues).
    Prior Authorization

    Prior authorization requirement

    Prior authorization is required for iDose TR (J7355); submit medical records supporting the request and ensure the criteria below are met before coverage is considered.

    • Medical records must document diagnosis, prior therapy trials and failures, and reasons for failure.
    • Age restrictions are listed as N/A but required documentation remains mandatory.
    Prior Authorization

    Prior authorization required

    Prior authorization is required for iDose TR (J7355) when the patient has open‑angle glaucoma or ocular hypertension and meets the specified prior therapy requirements; include supporting medical records.

    • Provide documentation that the patient tried and failed one generic PGA plus Durysta, or is unable to use Durysta and tried and failed two generic PGAs.
    • Define failure per policy (inadequate response, intolerance, or demonstrated compliance issues).
    Prior Authorization

    PA/ST required for iDose TR (J7355)

    Prior authorization and step therapy apply for iDose TR (HCPCS J7355); ensure required medical information and prior therapy documentation are submitted with the PA request.

    • PA/ST applies to J7355; include medical records documenting diagnosis and prior trials.
    • Follow the alternate pathways (Durysta pathway or two-PGA pathway) as applicable.
    Prior Authorization

    PA required for iDose TR J7355

    Prior authorization is required for iDose TR (travoprost intracameral implant J7355); submit medical records showing diagnosis of open‑angle glaucoma or ocular hypertension and prior topical prostaglandin trial documentation.

    • Document failure reasons (inadequate response, intolerance, or compliance issues) for each prior trial.
    • PA is required for one-time administration per FDA labeling when criteria are met.
    Billing Rule

    PA required for J7355 (iDose TR)

    Prior authorization is required for iDose TR (J7355) as a one-time administration per FDA-approved labeling; approval requires meeting the stated prior‑therapy criteria and providing supporting medical records.

    • One-time administration coverage per FDA labeling contingent on meeting prior therapy pathways.
    • Medical records must demonstrate prior topical PGA trials and Durysta use or inability to use Durysta.
    Prior Authorization

    PA required — iDose TR J7355

    Prior authorization is required for iDose TR (HCPCS J7355); submit the required documentation demonstrating diagnosis and prior therapy failure per policy before implant will be approved.

    • Include records of prior trial(s) of generic prostaglandin eye drops and Durysta pathway details where applicable.
    • Confirm the requested eye has not previously received IDOSE TR.
    Step Therapy

    Step therapy requirement

    Step therapy requires that providers document trials and failures of preferred or more cost‑effective drugs before prescribing non‑preferred agents; failure must be shown in medical records (inadequate response or intolerance).

    • Step Therapy applies to MAPD members not currently receiving the Part B drug.
    • Document inadequate response or intolerance in the medical record when requesting escalation.
    Documentation Required

    Referenced numbered clinical criteria

    Refer to the policy's numbered clinical criteria (1–4) when preparing PA requests; for transthyretin-related indications this includes documentation of a TTR mutation (e.g., V30M) and baseline PND/FAP staging.

    • Include genetic documentation of a pathogenic TTR mutation where required.
    • Provide baseline PND score (≤ IIIb) and/or FAP Stage 1 or 2 as applicable.
    Step Therapy

    Step therapy — try Attruby first

    For Amvuttra in transthyretin amyloid cardiomyopathy, the patient must first try and fail Attruby before Amvuttra (J0225) will be covered; document prior trial and failure in the medical records.

    • Document trial of Attruby and evidence of inadequate response or intolerance.
    • Include confirmation of diagnosis and other required Amvuttra medical information.
    Step Therapy

    Evenity step therapy

    Evenity requires prior trial and failure of Prolia before coverage; document failure (intolerance, decreased BMD vs prior DEXA, new fracture while on therapy, or contraindication) and include that an endocrinologist prescribed or was consulted.

    • Evenity coverage is limited to 12 months per lifetime.
    • Prescriber must be an endocrinologist.
    Step Therapy

    Intravitreal agent step therapy

    Intravitreal agents require step therapy: providers must document a trial of Avastin (bevacizumab) before aflibercept/Eylea family products and follow Eylea HD failure definitions where applicable.

    • Document trial and failure of Avastin in the medical records.
    • For Eylea HD, adhere to dose/failure criteria (e.g., maintenance dosing tried before deeming failure).
    Step Therapy

    Exdensur step therapy

    Exdensur requires prior controller therapy trials and an eosinophil count ≥150; include specialist prescribing/consultation documentation (allergist, immunologist, or pulmonologist) and prior therapy records.

    • Document elevated eosinophils (≥150) and prior controller therapy trials or hospitalization history as applicable.
    • Prescriber must be or consult an allergist, immunologist, or pulmonologist.
    Step Therapy

    Biosimilar step therapy requirement

    Biosimilar step therapy: for listed trastuzumab biosimilars, providers must document trials of the specified biosimilars (Trazimera AND Kanjinti) before requesting Hercessi or Herzuma.

    • Medical records must show trials and reasons for failure of the biosimilars.
    • Coverage duration typically 1 year; dosing per FDA labeling.
    Step Therapy

    Step therapy requirement (topical prostaglandin)

    For iDose TR, patient must have tried and failed topical prostaglandin therapy as specified: either one generic PGA plus Durysta, or if Durysta cannot be used, two generic PGAs; document trials and reasons for failure.

    • Define 'failed' trials in the record (inadequate response, intolerance, or compliance issues).
    • Include specifics of topical agents tried (e.g., latanoprost, bimatoprost, travoprost) and Durysta details.
    Step Therapy

    Required prior topical therapy

    Patients must try one generic prostaglandin eye drop and Durysta, or if Durysta is not usable, two generic prostaglandin eye drops, and document failure per policy before iDose TR will be approved.

    • Provide medical records showing prior topical PGA trials and Durysta trial or documented inability to use Durysta.
    • Failure is defined as inadequate response, intolerance, or demonstrated compliance issues.
    Step Therapy

    Step therapy

    Step therapy requires prior trials of generic topical prostaglandin eye drops as outlined in the coverage criteria; document the trials, outcomes, and reasons for failure in the medical records.

    • List specific generic PGAs tried and dates/durations.
    • Document reasons for failure (inadequate response, intolerance, or compliance issues).
    Step Therapy

    Step therapy pathway for iDose TR

    Step therapy requires documented prior use of generic topical prostaglandin(s) and, depending on Durysta availability, either one failed PGA plus Durysta or two failed PGAs if Durysta cannot be used.

    • Document inability to use Durysta when claiming the two‑PGA pathway.
    • Provide clinical justification and supporting records for each failed trial.
    Step Therapy

    Step therapy pathway

    Step therapy requires trial and failure of specified generic topical prostaglandin eye drops (latanoprost, bimatoprost, or travoprost) and, depending on pathway, Durysta; document trials and outcomes in the medical record.

    • Ensure records include dates, dosages, and documented reason the trial is considered failed.
    • Attach Durysta trial documentation or documented contraindication/inability to use Durysta if applicable.
    Documentation Required

    Required supporting medical records

    Provide medical records supporting the PA request for all drugs requiring documentation; include prior therapy trials, diagnostic test results, specialist consultations, and objective measures as specified by the drug criteria.

    • Include prior therapies and responses, genetic testing (e.g., TTR mutation V30M) when required, baseline scores (PND, MG-ADL, EDSS) where applicable.
    • For specialist-restricted drugs, include consultation notes or prescriber specialty documentation.
    Documentation Required

    Required medical information (TTR conditions)

    For Amvuttra and other transthyretin-targeted therapies, include documentation of a pathogenic TTR mutation (example V30M), baseline PND score ≤ IIIb and/or FAP Stage 1 or 2, and clinical signs/symptoms in the PA submission.

    • Attach genetic testing results showing the TTR mutation.
    • Provide baseline neurologic assessments (PND score) and clinical notes describing motor/autonomic neuropathy symptoms.
    Documentation Required

    Diagnosis confirmation

    Confirm and document the diagnosis with appropriate testing for transthyretin amyloid cardiomyopathy (wild-type or hereditary) when submitting PA for Amvuttra; include diagnostic test results in the medical records.

    • Include imaging, biopsy, or other confirmatory testing results as applicable.
    • Document that the patient is ≥18 years of age when applicable.
    Documentation Required

    Age documentation

    Document the patient’s age in the PA request; for transthyretin‑related indications the patient must be at least 18 years of age.

    • Include date of birth and age in the medical record extract submitted with the PA.
    • Age requirement: ≥18 years for the specified Amvuttra indications.
    Documentation Required

    Required documentation

    Provide required medical records documenting diagnosis confirmation, prior therapies, baseline assessments, and clinical signs/symptoms as specified in the drug criteria when submitting a PA.

    • For TTR therapies: TTR mutation, baseline PND/FAP staging, clinical symptoms.
    • For iDose TR: prior topical PGA trials, Durysta trial or inability to use Durysta, and evidence the requested eye has not received prior IDOSE TR.
    Documentation Required

    Required clinical documentation

    Provide clinical documentation that confirms diagnosis and, where applicable, genetic testing and baseline disability measures (e.g., PND score ≤ IIIb, FAP Stage 1–2) for transthyretin-related indications.

    • Attach genetic test reports and baseline neurologic assessments.
    • Document clinical signs such as motor disability or autonomic neuropathy.
    Documentation Required

    Required medical information (prior therapies)

    Medical records supporting the PA request must include prior therapies and documented responses to treatment for drugs with step‑therapy or prior‑therapy requirements.

    • Include dates, dosages, duration, and the clinical rationale for failure or intolerance.
    • For biosimilar sequencing, document trials of the specified biosimilars.
    Documentation Required

    Required medical records and prior therapy documentation

    Include documentation of prior therapies and responses when requesting PA for agents with prior‑therapy requirements; this includes specialist consultation notes where required.

    • For Epysqli and similar agents, include neurologist consultation notes and prior biologic therapy history.
    • Document objective measures of response for reauthorization (e.g., decreased relapse rate, improved MG‑ADL).
    Documentation Required

    Evkeeza LDL-C documentation

    For Evkeeza (evinacumab J1305), submit the most recent LDL‑C level with the PA request and document specialist prescriber or consultation (cardiologist, endocrinologist, or lipidologist).

    • Include the latest LDL‑C laboratory result in the medical record submission.
    • Document that the prescriber is, or consulted with, an appropriate specialist.
    Documentation Required

    Required medical records (hemophilia/marstacimab)

    Provide medical records supporting requests for hemophilia prophylaxis agents and marstacimab, including hemophilia diagnosis documentation and prior prophylaxis trials; prescriptions must be written by a hematologist.

    • Document hemophilia type and absence of inhibitors where required.
    • Provide records of trials of prior prophylaxis agents and rationale for progression to marstacimab.
    Documentation Required

    Required clinical documentation (iDose TR)

    Medical records supporting PA for ophthalmic implants must include prior topical prostaglandin trials, Durysta trial or documented inability to use Durysta, and evidence of open‑angle glaucoma or ocular hypertension.

    • Document specific topical agents tried, durations, and reasons for failure.
    • If claiming inability to use Durysta, include clinical rationale and supporting notes.
    Denial Risk

    Exclusion and documentation-related denial risk

    Use of certain drugs in combination with other prophylactic agents for hemophilia A or B is an exclusion and lack of required documentation may result in denial; ensure combination therapy is not used and submit complete records.

    • Do not request concurrent use of marstacimab with other hemophilia prophylaxis agents.
    • Provide full prior therapy documentation to avoid exclusion‑based denials.
    Denial Risk

    Insufficient documentation

    Requests lacking medical records, genetic confirmation (TTR mutation), baseline PND ≤ IIIb and/or FAP Stage 1–2, or clinical signs/symptoms for transthyretin conditions may be denied; include complete supporting documentation with the PA.

    • Attach genetic test results and baseline neurologic assessments where required.
    • Document clinical signs such as motor disability or autonomic neuropathy in submitted records.
    Denial Risk

    Documentation-based denial risk

    Lack of required medical records documenting TTR mutation, baseline PND score ≤ IIIb or FAP Stage 1–2, and clinical signs/symptoms may trigger denial for transthyretin therapies; ensure these items are provided.

    • Provide clear documentation of mutation and staging in the medical records.
    • Include baseline functional assessments and clinician notes describing symptoms.
    Denial Risk

    Diagnosis confirmation required

    Failure to confirm diagnosis with appropriate testing for transthyretin amyloid cardiomyopathy (wild‑type or hereditary) may result in denial; include diagnostic test results with the PA.

    • Attach confirmatory test results (e.g., imaging, biopsy) when submitting the PA.
    • Document that the patient meets age and other specified criteria.
    Denial Risk

    Documentation and diagnosis confirmation required

    Lack of documentation confirming diagnosis or prior therapies and responses may trigger denial for therapies requiring such evidence; provide complete medical records with PA requests.

    • Include prior therapy timelines, objective measures of response, and clinician notes.
    • For reauthorization, include documentation of clinical improvement where required.
    Denial Risk

    Evenity cumulative use cap

    Evenity use beyond 12 months per lifetime is not covered; do not request reauthorization for cumulative use exceeding the 12‑month lifetime limit.

    • Document prior Evenity exposure and cumulative duration when requesting coverage.
    • If prior therapy exceeds 12 months, requests will be considered not medically necessary.
    Denial Risk

    Hympavzi combination and prescriber restrictions

    Marstacimab must not be used in combination with other prophylaxis drugs for hemophilia A or B and the prescription must be written by a hematologist; combination use or lack of prescriber documentation may trigger denial.

    • Include hematology prescriber information on the PA submission.
    • Do not request concurrent use with other hemophilia prophylaxis agents.
    Denial Risk

    iDose TR prior-treatment exclusion

    Requests for iDose TR (J7355) will be denied if the requested eye has previously received IDOSE TR (prior same-device treatment); confirm and document prior eye‑specific treatments before submission.

    • Document the treatment history for the requested eye and confirm no prior IDOSE TR implantation.
    • If prior IDOSE TR is present for the requested eye, do not submit for coverage.
    Denial Risk

    Failure to provide required prior therapy documentation

    Failure to provide medical records or to document required prior topical prostaglandin trials and/or Durysta use (or inability to use Durysta) for iDose TR requests may result in denial; include complete trial documentation.

    • Provide dates, agents, duration, and reasons for failure for each topical PGA trial.
    • If Durysta was tried, include documentation of trial and outcome; if not usable, document clinical rationale.
    Denial Risk

    Denial triggers (iDose TR)

    Lack of supporting medical records, absence of diagnosis of open‑angle glaucoma or ocular hypertension, or failure to document required prior topical prostaglandin trials may trigger denial for iDose TR requests.

    • Ensure the PA includes clinical diagnosis notes and evidence of prior trial failures per policy.
    • Document reasons and objective findings supporting each claim of failure.
    Denial Risk

    Denial triggers (documentation)

    Failure to provide supporting medical records or to meet the required prior therapy criteria for iDose TR may trigger denial; submit complete records demonstrating diagnosis and prior trial failures.

    • Include provider notes, medication histories, and objective measures documenting inadequate response or intolerance.
    • If claiming inability to use Durysta, include documented clinical barriers.
    Denial Risk

    Requests may be denied if patient does not meet glaucoma criteria

    Requests may be denied if the patient does not have a diagnosis of open‑angle glaucoma or ocular hypertension or has not met the required prior topical prostaglandin trial criteria; confirm diagnosis and prior trials in the PA submission.

    • Provide clear diagnostic documentation and prior treatment history.
    • Denials will be issued when required criteria are not met or documented.
    Denial Risk

    Denial triggers (prior trial unmet)

    A PA request may be denied for iDose TR if the patient lacks open‑angle glaucoma or ocular hypertension or has not met the required prior trial criteria (one PGA + Durysta or two PGAs if Durysta unusable); include detailed trial documentation to avoid denial.

    • Document specific PGA trials, Durysta trial or inability to use Durysta, and outcomes.
    • Attach clinical notes demonstrating inadequate response, intolerance, or compliance issues as the reason for failure.
    Denial Risk

    Missing prior therapy documentation

    Lack of documentation showing prior trial failures with required topical prostaglandin drops and/or Durysta will trigger denial for iDose TR; ensure all prior trial records and the reason each trial failed are submitted.

    • Include dates, agents, dosing, adherence information, and clinician assessment of response for each prior trial.
    • Provide Durysta trial documentation or clinical justification if Durysta is not usable.
    Documentation Required

    Documentation of indication and prior therapy required

    Documentation must show the patient has open‑angle glaucoma or ocular hypertension and has met the required prior topical/Durysta trial criteria before iDose TR will be approved; submit complete clinical records with the PA.

    • Medical records should clearly state the diagnosis and describe prior therapy attempts and outcomes.
    • Failure reasons must align with policy definitions (inadequate response, intolerance, or compliance issues).
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Initial Authorization / Step Therapy — Criteria

    inv-179: Initial step therapy

    Step therapy requires trying preferred or more cost‑effective drugs first; failure (inadequate response or intolerance) must be documented.

    Initial step therapy: Member must try preferred or specified alternative Part B/Part D drugs first; documented failure (inadequate response or intolerance) is required to progress to the non‑preferred agent.

    Applies to MAPD members not currently receiving the Part B drug.

    inv-180: Initial therapy — ATTR‑FAP

    Initial authorization requires submission of the following documentation:

    Initial therapy requirements — ATTR‑FAP: Medical records supporting the request; documentation of a transthyretin (TTR) mutation (e.g., V30M); baseline PND score ≤ IIIb and/or FAP Stage 1 or 2; documentation of clinical signs and symptoms.PND <= IIIb or FAP Stage 1-2

    inv-181: Initial therapy requirements

    Initial authorization requires meeting all listed criteria:

    initial vutrisiran authorization: 1) Age ≥ 18 years; AND 2) For hATTR: documentation of TTR mutation (e.g., V30M), baseline PND ≤ IIIb and/or FAP Stage 1–2 and clinical signs/symptoms; AND 3) For cardiomyopathy: confirmation of diagnosis with appropriate testing; AND 4) Submission of supporting medical records.Age >= 18 years; PND <= IIIb or FAP 1-2

    Effective 1/1/2026 for J0225 entries.

    inv-182: Initial therapy requirements (diagnosis & baseline)

    Initial therapy coverage requires documented diagnosis and baseline assessments.

    Age and diagnosis: Patient is ≥ 18 years and has confirmed transthyretin amyloid cardiomyopathy via appropriate testing; may require documentation of TTR mutation (e.g., V30M) and baseline polyneuropathy disability.Age >= 18 years

    inv-183: Initial therapy criteria (Amvuttra)

    Initial coverage for Amvuttra is available when the following are met:

    Initial therapy nodes: Confirmation of diagnosis; age ≥18; prior trial and failure of Attruby for cardiomyopathy indication; and medical records provided documenting prior therapies and responses.

    Dose per FDA labeling; coverage duration up to 1 year.

    inv-184: Initial therapy criteria (Amvuttra)

    Exdensur initial therapy nodes:

    Eosinophil threshold: Eosinophil count ≥150 cells/µL required.>= 150

    Must have prior controller therapy trials or exacerbation/hospitalization history as applicable and be prescribed by appropriate specialist.

    inv-185: Hympavzi initial therapy

    Hympavzi initial dosing and prior prophylaxis trials:

    Loading and maintenance dosing: Loading dose 300 mg (two 150 mg injections) SC; maintenance 150 mg weekly starting one week after loading; dose adjustments to 300 mg weekly require documented medical necessity.

    Prior prophylaxis trials required per hemophilia type.

    inv-186: Marstacimab initial therapy

    Initial dosing requirements for marstacimab:

    Marstacimab initial dosing: Loading dose: 300 mg (two 150 mg injections) subcutaneously; then maintenance 150 mg weekly starting one week after loading dose; increases to 300 mg weekly require documentation of medical necessity.

    Prescription must be written by a hematologist and prior prophylaxis trials required.

    inv-187: Initial therapy

    Initial authorization: Medical records provided; diagnosis of open‑angle glaucoma or ocular hypertension; prior trials per specified pathways (see iDose TR criteria).

    If patient cannot use Durysta, requirement is two failed generic topical prostaglandins.

    inv-188: Initial coverage

    Initial coverage requires documented prior therapies and diagnosis

    Initial drug coverage: Medical records provided AND diagnosis of open‑angle glaucoma or ocular hypertension AND either (a) trial and failure of one generic prostaglandin eye drop plus Durysta; OR (b) inability to use Durysta and trial/failure of two generic prostaglandin eye drops.

    'Failed' defined as inadequate response, intolerance, or compliance issues.

    inv-189: Initial therapy (single node)

    Initial authorization nodes: Medical records supporting the request; diagnosis of open‑angle glaucoma or ocular hypertension; and prior therapy per options a or b (see coverage criteria).

    inv-190: Initial therapy (single node)

    Initial coverage nodes: Patient has open‑angle glaucoma or ocular hypertension; plus either: (a) tried and failed one generic prostaglandin (latanoprost, bimatoprost, travoprost) AND Durysta, or (b) unable to use Durysta and tried and failed two generic topical prostaglandin eye drops.

    Failure defined as inadequate response, intolerance, or compliance issues.

    inv-191: Initial therapy (single node)

    Initial coverage nodes: Patient has diagnosis of open‑angle glaucoma or ocular hypertension AND meets one of the prior therapy pathways (trial/failure of required topical prostaglandin(s) and Durysta as applicable).

    inv-192: Initial therapy requirements (two nodes)

    Indication: Patient has open‑angle glaucoma or ocular hypertension.
    Prior therapy: (a) Trial and failure of one generic prostaglandin topical drop plus Durysta; OR (b) If patient cannot use Durysta, trial and failure of two generic topical prostaglandin drops.

    Failure defined as inadequate response, intolerance, or documented compliance issues.

    inv-193: Prior topical and Durysta trial requirements

    Initial coverage requires prior topical therapy and/or Durysta trials.

    Prior therapy options: Option A: Trial and failure of one generic prostaglandin eye drop AND Durysta; OR Option B: Patient unable to use Durysta AND trial and failure of two generic topical prostaglandin eye drops.

    Failure = inadequate response, intolerance, or compliance issues.

    inv-194: Initial Therapy (single node)

    Initial therapy requirements: Patient has open‑angle glaucoma or ocular hypertension AND has tried and failed one generic topical prostaglandin (unless alternate Durysta pathway applies) or has failed two prostaglandin drops if Durysta not usable.

    Failed = inadequate response, intolerance, or compliance issues.

    inv-195: Continuation / coverage duration

    Coverage duration guidance

    Duration: Coverage duration to be within accepted standards of medical practice; many Part B drugs are authorized for up to 1 year when specified.Up to 1 year

    See drug‑specific entries for precise duration limits (e.g., Evenity 12 months per lifetime).

    Reauthorization and Continuation Requirements

    inv-195: Continuation / coverage duration

    Coverage duration guidance

    Duration: Coverage duration to be within accepted standards of medical practice; many Part B drugs are authorized for up to 1 year when specified.Up to 1 year

    See drug‑specific entries for precise duration limits.

    inv-197: Epigslist reauthorization

    Reauthorization/continuation requirements (examples):

    Epigslist reauthorization: Documentation of clinical response required for reauthorization (e.g., decreased relapse rate for NMOSD; improvement in MG‑ADL for MG; normalization of hematologic markers for aHUS; clinical improvement for PNH).

    Therapy must not be used in prohibited combinations per indication.

    inv-196: Entyvio reauthorization

    Reauthorization/continuation requirements (examples):

    Epigslist reauthorization — NMOSD: For NMOSD: documentation of decreased relapse rate is required for reauthorization; therapy must not be used in combination with Ultomiris, Uplizna, Enspryng, or other NMOSD medications.

    EDSS ≤7 required at baseline per initial criteria.

    Epigslist reauthorization — MG: For myasthenia gravis: documentation of improvement in MG‑ADL total score from baseline required for reauthorization; not used in combination with similar MG therapies.MG‑ADL improvement

    Baseline MG‑ADL ≥6 required at initiation.

    Denial Risk

    Evenity cumulative use cap — not covered >12 months

    Evenity is limited to 12 months per lifetime; do not request reauthorization beyond the 12‑month cumulative cap.

    Step Therapy Pathways and Required Trials

    RequirementDetails
    Try preferred/more cost-effective drugs first
    Step therapy requires trying a preferred or more cost-effective drug before a non-preferred drug; failure must be documented as inadequate response or intolerance (provider/medical records). Applies to MAPD members not currently receiving the Part B drug.
    Referenced itemPolicy note
    Numbered clinical criteria (1–4)
    Policy references staged numbered criteria including requirement to document transthyretin (TTR) mutation (example V30M) and baseline polyneuropathy disability (PND) score and clinical signs/symptoms as part of eligibility.
    Step requirementPolicy text
    Attruby trial required before Amvuttra
    For transthyretin amyloid cardiomyopathy (wild-type or hereditary), the patient must first try and fail Attruby prior to coverage of Amvuttra (vutrisiran).
    Product exampleStep therapy requirement
    Fulphila (pegfilgrastim-jmdb)
    Must first try Neulasta, Udenyca, AND Nyvepria before Fulphila is approved; coverage duration up to 1 year.
    ReferenceRequirement
    Trastuzumab biosimilars
    Must first try the specified biosimilars Trazimera AND Kanjinti prior to coverage of branded trastuzumab products (e.g., Herceptin, Herceptin Hylecta, Hercessi, Herzuma); typical coverage duration 1 year.
    Ophthalmic classStep requirement
    Aflibercept / Eylea family
    Must try Avastin (bevacizumab) prior to coverage of aflibercept/Eylea family agents; failure definitions and dosing requirements apply as specified (Eylea HD failure definitions noted).
    Biosimilar requirementApplies to
    Trial of Trazimera AND Kanjinti required
    Must try Trazimera AND Kanjinti before coverage of Hercessi or Herzuma (trastuzumab biosimilars/biologics).
    iDose TR prior therapiesPolicy detail
    Topical prostaglandin drops + Durysta pathway
    For iDose TR, patient must have tried and failed one generic topical prostaglandin eye drop (e.g., latanoprost, bimatoprost, travoprost) AND Durysta, with failure defined as inadequate response, intolerance, or compliance issues.
    iDose TR alternative pathwayPolicy detail
    Two generic topical prostaglandin drops pathway
    If patient cannot use Durysta, trial and failure of two generic topical prostaglandin eye drops (e.g., latanoprost, bimatoprost, travoprost) is required before iDose TR.
    StepRequirement
    Prior topical prostaglandin therapy required
    Step: require prior topical prostaglandin therapy — either one generic prostaglandin plus Durysta OR two generics if Durysta is not usable; 'failed' defined as inadequate response, intolerance, or compliance issues.
    Trial optionsDetails
    Number of topical prostaglandin trials
    Policy requires trial of specified number of generic topical prostaglandin eye drops and/or Durysta depending on patient ability to use Durysta: (a) one generic PGA + Durysta OR (b) two generic PGAs if Durysta unusable.
    Prior trialsConsideration
    Required prior topical trials and Durysta consideration
    Prior trial(s) of specified generic topical prostaglandin(s) and consideration of Durysta per criteria must be documented in medical records for authorization of iDose TR.
    PathwayRequirement
    Topical PGA trial(s) + Durysta pathway
    Trial of specified generic topical prostaglandin eye drop(s) and consideration of Durysta per pathway: either one PGA + Durysta or two PGAs if Durysta not usable; documented failure required.
    Prior therapy(s)Documentation
    Topical prostaglandin(s) and Durysta per criteria
    Trial(s) of topical prostaglandin(s) and Durysta must be documented; 'failed' defined as inadequate response, intolerance, or demonstrated compliance issues with glaucoma eye drops.
    Coverage optionsStep requirement
    Generic topical PGA(s) and Durysta before implant
    Trial of generic topical prostaglandin(s) and Durysta per the coverage options described (one generic PGA + Durysta OR two generics if Durysta unusable) before approval of the intracameral implant (iDose TR).
    Minimum trial requirementPolicy language
    One PGA (or two if Durysta not usable)
    Member must have tried and failed at least one generic prostaglandin analog (e.g., latanoprost, bimatoprost, travoprost) — OR two generics if Durysta cannot be used — with failure defined as inadequate response, intolerance, or compliance issues.

    Quantity, Duration and Administration Limits

    Evenity quantity limit (months)
    Quantity limit12 months per lifetime
    DrugEvenity (romosozumab-aqqg, J3111)
    RequirementMust try and fail Prolia prior to approval
    iDose TR administration frequency
    Administration frequencyOne-time administration per FDA-approved labeling
    Drug/codeiDose TR (travoprost intracameral implant) — HCPCS J7355
    Coverage noteApproval requires meeting prior topical/Durysta trial criteria and documentation

    inv-81: Coverage duration guidance (typical up to 1 year)

    Coverage duration guidance (typical up to 1 year where specified; some agents have specific limits):

    Typical coverage duration: When specified, coverage duration is commonly up to 1 year; some therapies have unique limits (e.g., Evenity limited to 12 months per lifetime).Up to 1 year

    Refer to drug‑specific entries for exact duration rules.

    Site of Care and Administration Notes

    Note

    Document site of care for infusion/office administration

    Part B drugs are typically administered by infusion or injection furnished incident to a physician or provider service (infusion center or office); document site of care and administration details in the claim/PA.

    Billing Rule

    Infusion center dosing approved per FDA labeling

    Dose approvals for infusion‑administered Part B drugs will follow FDA‑approved labeling or accepted standards of medical practice; include dosing rationale if outside standard labeling.

    Billing Rule

    Hospital outpatient — document one‑time intracameral implant administration

    For hospital outpatient administration, document that the one‑time intracameral implant is being administered per FDA labeling and include supporting PA documentation.

    Billing Rule

    Office/outpatient one‑time administration — include PA and docs

    For office/outpatient one‑time administrations (e.g., iDose TR) ensure PA and documentation support the one‑time administration per FDA labeling.

    Note

    If site not specified, provide rationale with PA

    If site of care is not specified in the request, include rationale and documentation for the chosen site when submitting PA to avoid processing delays.

    Biosimilar Preference and Required Trials

    Billing Rule

    Alymsys — must try Mvasi AND Zirabev first

    Alymsys (bevacizumab‑maly) coverage requires trying Mvasi AND Zirabev first for all medically‑accepted indications; document trials of those biosimilars in the PA.

    Billing Rule

    Trastuzumab preference — try Trazimera AND Kanjinti first

    Trastuzumab (Herceptin) products require that providers document trials of Trazimera AND Kanjinti before Herceptin family products will be covered.

    Billing Rule

    Trazimera AND Kanjinti required before Hercessi

    Trastuzumab biosimilar preference: providers must document trials of Trazimera AND Kanjinti before coverage of Hercessi is authorized.

    Billing Rule

    Entyvio — must try Inflectra or Renflexis and Hadlima first

    Entyvio coverage requires trying Inflectra OR Renflexis and Hadlima first; document those prior biosimilar trials in the PA submission.

    Billing Rule

    Must try Trazimera AND Kanjinti before Hercessi

    Providers must document trials of Trazimera AND Kanjinti before Hercessi will be covered; include records of those biosimilar trials in the PA.

    Billing Rule

    Must try Trazimera AND Kanjinti before Herzuma

    Providers must document trials of Trazimera AND Kanjinti before Herzuma will be covered; include trial documentation in the PA submission.

    Background and Scope

    Medicare Part B covers outpatient drugs and biologics that are typically administered by infusion or injection and provided incident to a physician service rather than self-administered therapies. HAP follows CMS National/Local Coverage Determinations and, when absent, medically accepted compendia and current evidence to determine coverage criteria under Part B.

    Definitions and Clinical Thresholds

    Part B drug definition
    DefinitionOutpatient prescription drugs and biologicals eligible for coverage under Medicare Part B; typically infused or injected and not usually self-administered
    Site of careAdministered incident to a physician or provider service (clinical settings)
    RelevanceDetermines Part B benefit and prior authorization pathways
    Step Therapy (ST) definition
    DefinitionStep Therapy (ST) requires trying a preferred or more cost-effective drug before a non-preferred drug; failure (inadequate response or intolerance) must be documented
    Applies toMembers in MAPD not currently receiving the Part B drug
    DocumentationFailure must be indicated by provider or medical records
    Medically Accepted Indication (MAI)
    DefinitionMedically Accepted Indication (MAI): indications defined by CMS (NCD/LCD/LCA); if absent, use CMS‑approved compendia and authoritative literature
    Use in policyHAP follows NCD/LCD/LCA when available; otherwise creates criteria based on compendia and evidence
    ImplicationUnlabeled uses may be covered if deemed MAI by HAP clinical reviewer or Medical Director
    Baseline PND score definition
    DefinitionBaseline polyneuropathy disability (PND) score: less than or equal to IIIb
    ContextUsed to determine eligibility for Amvuttra/ATTR‑FAP coverage
    Must be documentedPND score must be included in medical records submitted with PA
    FAP Stage definition
    DefinitionFAP Stage: Stage 1 or 2
    ContextAcceptable baseline FAP stages for ATTR‑FAP coverage
    DocumentationStage must be recorded in supporting medical records
    PND / FAP baseline severity
    DefinitionBaseline severity requirement: PND score <= IIIb and/or FAP Stage 1 or 2
    Applies toTransthyretin-related familial amyloid polyneuropathy (hATTR) and ATTR‑FAP
    DocumentationRequired as part of numbered medical information for PA
    TTR mutation
    DefinitionTTR mutation: documented pathogenic transthyretin (TTR) mutation required (example: V30M)
    PurposeGenetic confirmation required for ATTR-related coverage
    DocumentationMutation example (V30M) may be cited in medical records submitted with PA
    TTR mutation example V30M
    Example mutationV30M cited as an example of a documented transthyretin mutation
    ContextUsed in required medical information for ATTR‑FAP authorization
    DocumentationInclude genetic test result indicating mutation in PA submission
    Transthyretin amyloid cardiomyopathy — definition reference
    DefinitionTransthyretin amyloid cardiomyopathy (wild-type or hereditary): clinical diagnosis requiring confirmation with appropriate testing
    Coverage requirementConfirmation of diagnosis with appropriate testing is required for Amvuttra J0225 coverage
    Age>= 18 years for cardiomyopathy indication
    MG-ADL definition
    DefinitionMG-ADL: Myasthenia Gravis Activities of Daily Living score; baseline >=6 required for Epysqli in MG
    Use for reauthImprovement in MG-ADL from baseline required for reauthorization
    DocumentationBaseline MG-ADL must be included in PA request
    AQP4 antibody positive definition
    DefinitionAQP4 antibody positive: presence of anti‑aquaporin‑4 antibodies required for Epysqli coverage in NMOSD
    ContextPart of NMOSD indication criteria for Epysqli (eculizumab)
    DocumentationAQP4 antibody status must be documented in medical records for PA
    Failed — definition
    DefinitionFailed: a trial with inadequate response or intolerance, or demonstrated compliance issues (for glaucoma drops)
    ContextUsed to define prior‑therapy failure for iDose TR and other step‑therapy requirements
    DocumentationProvider or medical records must indicate reason for failure
    Failed — definition (duplicate)
    DefinitionFailed (therapy): inadequate response, intolerance, or demonstrated compliance issues with glaucoma eye drops
    Applied toiDose TR prior therapy pathway and step therapy definitions
    EvidenceFailure reason must be documented in submitted records
    Failed — definition (duplicate)
    DefinitionFailed: trial with inadequate response or intolerance, or demonstrated compliance issues
    RelevanceRepeated across iDose TR criteria to define prior therapy failure
    DocumentationMust be shown in PA supporting records
    Failed (therapy) definition
    DefinitionFailed (therapy): trial with inadequate response or intolerance, or demonstrated compliance issues
    UsageDefines step‑therapy failure for topical prostaglandin trials before iDose TR
    Provider noteProvider should document reason for failure (e.g., intolerance, nonresponse, compliance)
    Failed — definition (duplicate)
    DefinitionFailed: inadequate response, intolerance, or demonstrated compliance issues with glaucoma eye drops
    ConsistencyDefinition reiterated across multiple iDose TR policy sections
    ImplicationDetermines eligibility for implant when prior therapies have failed
    Failed (therapy) definition (duplicate)
    DefinitionFailed (therapy): a trial with inadequate response or intolerance, or demonstrated compliance issues
    ApplicationUsed to evaluate prior topical prostaglandin therapy before implant approval
    Required documentationMedical records must state nature of failure
    Failed trial — definition
    DefinitionFailed trial: inadequate response, intolerance, or demonstrated compliance issues
    ContextDefines step‑therapy failure for ophthalmic prostaglandin drops
    Evidence requirementProvider documentation required in PA submission
    Failed — definition (duplicate)
    DefinitionFailed: inadequate response, intolerance, or compliance issues
    UseRepeated definition across policy for prior‑therapy failure criteria
    NoteApplies to both single‑drop + Durysta and two‑drop pathways for iDose TR
    Failed — definition (duplicate)
    DefinitionFailed: a trial with inadequate response, intolerance, or demonstrated compliance issues (glaucoma drops)
    Practical guidanceDocument specific reason (e.g., side effects, insufficient IOP reduction, adherence problems)
    Required in PAMedical records must reflect failure per definition